June 25, 2018 07:53 AM EDT
R&D

Pan­cre­at­ic can­cer study fail­ure crip­ples a Mer­ri­mack drug, forc­ing a coup de grâce and pipeline re­treat

John Carroll

Editor & Founder

Eigh­teen months af­ter Mer­ri­mack $MACK re­struc­tured, sell­ing off its one mar­ket­ed drug, switch­ing out CEOs and cir­cling the wag­ons around three key can­cer drugs …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER
TRENDING NOW

Up­dat­ed: No­vo’s 23% weight loss with Ca­griSe­ma falls short of high ex­pec­ta­tions, new tri­al planned

The End­points 2024 win­ners and losers list: Who was up and who was down in bio­phar­ma

Mer­ck’s long-await­ed obe­si­ty move is an oral GLP-1 from Chi­na

Ma­jor PBM re­forms fea­ture in Con­gress' year-end spend­ing bill

What Trump’s FTC picks mean for bio­phar­ma deal­mak­ing and PBMs

Up­dat­ed: Ver­tex’s non-opi­oid pill dis­ap­points in mid-stage chron­ic pain study

A service from the Financial Times